OXFORD IMMUNE ALGORITHMICS LTD.
Raise of up to USD$10,000,000
About Oxford Immune Algorithmics Ltd.:
Oxford Immune Algorithmics Ltd. (“OIA” or the “Company”) is a deep-tech start-up incubated and co-developed by the UK Golden Triangle Universities (Oxford, Cambridge, and King’s College London) that applies Artificial General Intelligence (causal predictive & generative AI) based on symbolic regression and program synthesis to deliver decentralized mission-driven solutions to everyone today.
Overview
The intersection of biology and technology is poised to become increasingly vital. It holds immense potential for addressing numerous global challenges within healthcare.
As a company, OIA is focused on the intersection and the fusion of biology and technology. By leveraging the technological advancements of artificial general intelligence and diagnostics, OIA can revolutionize patient care and outcomes.
The integration of biology and technology enables the development of personalized medicine, where treatments are tailored to an individual. This approach can lead to more accurate diagnoses, targeted therapies, and improved drug development processes
Exchange: Private
Symbol: Private
Current Share Price: N/A
Use of Proceeds:
Commercial Build of Product
Operational and Administrative
Marketing
Launch & Return on Investment Case Studies
Inventory
Accounts Receivable and Working Capital
Corporate Structure & Valuation:
Pre-Money Valuation USD$39M.
Click Here to View the Company’s Website
Click Here to View the Company’s Investor Presentation
About Algocyte
Algocyte® is OIA’s flagship brand for a suite of generative Artificial General Intelligence-driven offerings that enable a full end-to-end individualised solution for precision health and predictive medicine.
Algocyte® assesses individual risk based on what it has learned from the user over time and uses guardrailed Generative AI to create prompts for humans to help clinicians in the process of diagnosis discovery and hypothesis testing.
This innovative feature helps triage users and can flag deviations from the user's own personal baseline while meaningfully quantifying change, allowing a level of personalization and sophistication not available before based on the analysis of clinical biomarkers, cross-referenced with lifestyle and clinical events reported by the user or their health professionals.
Click Here to View a recording of a demonstration of a functioning Alocyte device at Dubai Expo 2020
Investment Highlights/Risks:
OIA’s UK-based team are world-leading experts in AI, Computer Science, Physics and Microelectronics, associated with both Oxford and Cambridge Universities
OIA Founder, Dr. Hector Zenil, has published over 100 papers on the subject and helped to develop the factual answering AI engine behind both Siri and Alexa
Significant tail winds from three seismic shifts in healthcare have created new opportunities for continuous predictive health monitoring for improved clinical and financial outcomes to support personalized and precision medicine strategies
OIA’s Goal for Algocyte: By 2033 be the global ‘go to’ home monitoring AI Platform, with over 100 million users
Competitor Analysis:
Algocyte is patent-protected
There is currently no trading market for the securities offered in the Offering
Ascenta Offerings are available on a ‘first-come, first-served’ basis. Please express your interest in participating in this financing and we will attempt to hold a position for you. Once you have been confirmed, we will provide you with a Subscription Agreement and Ascenta’s Know Your Client information.
Members of Ascenta may invest alongside its network in this offering.
Closings of this financing will occur at the Company’s discretion.
The Company has agreed to pay a finder’s fee of up to 7% cash and 7% warrants for the financing.